Header Logo

Mary Fidler

Concepts (297)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Non-Small-Cell Lung
26
2024
240
4.730
Why?
Lung Neoplasms
28
2024
546
4.220
Why?
Antineoplastic Combined Chemotherapy Protocols
11
2021
228
1.580
Why?
Antineoplastic Agents
6
2022
178
1.140
Why?
Carcinoma, Squamous Cell
10
2023
172
1.060
Why?
Chemoradiotherapy
11
2023
61
0.910
Why?
Quinazolines
3
2012
15
0.850
Why?
Aged
38
2024
8595
0.730
Why?
Esophageal Neoplasms
2
2019
53
0.720
Why?
Neoplasm Staging
18
2024
358
0.700
Why?
Erlotinib Hydrochloride
2
2018
11
0.670
Why?
Esophagectomy
1
2019
23
0.650
Why?
Head and Neck Neoplasms
4
2023
148
0.650
Why?
Sarcopenia
1
2019
30
0.630
Why?
Kidney Glomerulus
5
2019
48
0.630
Why?
Female
44
2024
14520
0.630
Why?
Humans
58
2024
26260
0.610
Why?
Male
42
2024
14168
0.600
Why?
Biomarkers
5
2021
556
0.600
Why?
Drug Resistance, Neoplasm
2
2018
51
0.590
Why?
Prognosis
15
2022
710
0.590
Why?
Middle Aged
35
2024
8541
0.580
Why?
Inflammation Mediators
1
2018
64
0.570
Why?
Radiotherapy, Conformal
2
2014
21
0.560
Why?
Amyloidosis
5
2018
23
0.560
Why?
Kidney
6
2019
168
0.550
Why?
ErbB Receptors
6
2023
51
0.550
Why?
Oropharyngeal Neoplasms
4
2019
20
0.540
Why?
Pneumonectomy
2
2015
77
0.540
Why?
Neoadjuvant Therapy
4
2016
65
0.530
Why?
Muscle, Skeletal
1
2019
386
0.510
Why?
Retrospective Studies
23
2023
3283
0.490
Why?
Gene Dosage
2
2012
18
0.490
Why?
PTEN Phosphohydrolase
2
2011
7
0.470
Why?
Kidney Diseases
5
2014
105
0.460
Why?
Treatment Outcome
23
2021
3285
0.440
Why?
Social Class
1
2014
59
0.440
Why?
Postoperative Complications
2
2019
825
0.430
Why?
Glomerulonephritis
3
2019
20
0.420
Why?
Antibodies, Monoclonal, Humanized
3
2019
88
0.420
Why?
Receptor, IGF Type 1
1
2012
17
0.400
Why?
Survival Analysis
9
2021
242
0.390
Why?
Phosphatidylinositol 3-Kinases
1
2011
38
0.380
Why?
Neoplasm Recurrence, Local
5
2022
193
0.370
Why?
Immunotherapy
2
2021
55
0.360
Why?
Kaplan-Meier Estimate
7
2021
160
0.360
Why?
Cyclooxygenase 2
2
2014
28
0.330
Why?
Antineoplastic Agents, Immunological
2
2021
16
0.330
Why?
Biomarkers, Tumor
3
2021
199
0.330
Why?
Survival Rate
8
2018
315
0.310
Why?
Gastrointestinal Hemorrhage
1
2008
18
0.300
Why?
Glomerulonephritis, Membranous
2
2021
6
0.300
Why?
Kidney Transplantation
5
2019
116
0.290
Why?
Adult
17
2021
7516
0.280
Why?
Adenocarcinoma
3
2018
139
0.280
Why?
Glomerulonephritis, Membranoproliferative
2
2018
5
0.280
Why?
Mutation
4
2023
324
0.260
Why?
Proteomics
3
2018
92
0.260
Why?
Follow-Up Studies
8
2018
1722
0.240
Why?
Biopsy
8
2019
202
0.240
Why?
Combined Modality Therapy
7
2019
294
0.240
Why?
Induction Chemotherapy
2
2016
13
0.240
Why?
Databases, Factual
6
2019
315
0.240
Why?
United States
6
2019
2043
0.240
Why?
Nephritis, Interstitial
2
2014
7
0.230
Why?
Immunohistochemistry
4
2021
349
0.230
Why?
Body Composition
1
2024
64
0.220
Why?
Aged, 80 and over
11
2019
4594
0.220
Why?
Disease-Free Survival
6
2018
163
0.220
Why?
Radiotherapy, Intensity-Modulated
2
2014
36
0.220
Why?
Protein Kinase Inhibitors
3
2023
47
0.220
Why?
Laryngeal Neoplasms
1
2023
32
0.210
Why?
Cohort Studies
7
2021
1801
0.210
Why?
Primary Dysautonomias
1
2023
3
0.210
Why?
Molecular Targeted Therapy
2
2015
35
0.210
Why?
Mouth Neoplasms
1
2023
19
0.210
Why?
Programmed Cell Death 1 Receptor
2
2021
16
0.200
Why?
Immunosuppressive Agents
3
2019
130
0.200
Why?
Maytansine
1
2022
2
0.200
Why?
Immunoconjugates
1
2022
6
0.200
Why?
Nose Neoplasms
1
2022
40
0.200
Why?
Thoracic Neoplasms
1
2022
9
0.200
Why?
Immunoglobulin Light Chains
2
2011
6
0.190
Why?
Paranasal Sinus Neoplasms
1
2022
61
0.190
Why?
Body Weight
2
2024
137
0.190
Why?
Weight Gain
2
2012
62
0.190
Why?
N-Acetylglucosaminyltransferases
1
2021
3
0.180
Why?
Carcinoma, Large Cell
2
2018
12
0.180
Why?
Lupus Nephritis
1
2021
31
0.180
Why?
Chemoradiotherapy, Adjuvant
3
2015
16
0.170
Why?
B7-H1 Antigen
2
2021
9
0.170
Why?
Creatinine
3
2015
51
0.170
Why?
Autoantibodies
1
2021
78
0.170
Why?
Quality of Life
3
2023
606
0.170
Why?
Allografts
2
2019
206
0.170
Why?
Age Factors
4
2018
744
0.170
Why?
Immunoglobulin Light-chain Amyloidosis
1
2019
1
0.160
Why?
Neoplasms
1
2022
224
0.160
Why?
Human papillomavirus 16
1
2019
6
0.160
Why?
Papillomavirus Infections
2
2016
19
0.160
Why?
Antibodies, Monoclonal
2
2018
189
0.160
Why?
Taxoids
2
2015
10
0.160
Why?
Nephrotic Syndrome
1
2019
26
0.160
Why?
Biopsy, Fine-Needle
1
2019
60
0.160
Why?
Congo Red
1
2018
1
0.150
Why?
Tongue Neoplasms
1
2018
19
0.150
Why?
Small Cell Lung Carcinoma
1
2018
9
0.150
Why?
Registries
2
2022
170
0.150
Why?
Breast Neoplasms
1
2022
391
0.150
Why?
Immunoglobulin G
1
2018
92
0.140
Why?
Proton Pump Inhibitors
2
2014
13
0.140
Why?
Laser Capture Microdissection
2
2019
3
0.140
Why?
Palliative Care
2
2015
104
0.140
Why?
Leukocyte Count
1
2017
63
0.140
Why?
Lymphocytes
1
2017
57
0.130
Why?
Neutrophils
1
2017
89
0.130
Why?
Prevalence
2
2014
441
0.130
Why?
Immunoglobulins
1
2015
19
0.120
Why?
Multiple Myeloma
2
2012
16
0.120
Why?
Robotic Surgical Procedures
1
2015
28
0.120
Why?
Carcinoma
2
2015
65
0.120
Why?
Prostaglandins
1
2014
3
0.120
Why?
Predictive Value of Tests
3
2015
422
0.120
Why?
Anti-Bacterial Agents
2
2014
362
0.120
Why?
Patient Reported Outcome Measures
1
2019
493
0.120
Why?
Preoperative Care
1
2015
120
0.110
Why?
Actuarial Analysis
1
2014
8
0.110
Why?
Gene Expression Regulation, Neoplastic
2
2015
106
0.110
Why?
Academies and Institutes
1
2014
10
0.110
Why?
Cancer Care Facilities
1
2014
6
0.110
Why?
Propensity Score
1
2014
28
0.110
Why?
Parotid Gland
1
2014
17
0.110
Why?
Lymphatic Metastasis
1
2014
87
0.110
Why?
Intercellular Signaling Peptides and Proteins
1
2014
52
0.110
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2014
108
0.110
Why?
Health Services Accessibility
1
2014
104
0.110
Why?
Logistic Models
1
2014
353
0.100
Why?
Prospective Studies
1
2018
1665
0.100
Why?
Sulfonamides
2
2014
40
0.100
Why?
Young Adult
5
2018
1948
0.100
Why?
Disease Progression
4
2021
676
0.100
Why?
Lymphoma
1
2012
31
0.100
Why?
Spectrometry, Mass, Electrospray Ionization
1
2012
2
0.100
Why?
Tandem Mass Spectrometry
1
2012
21
0.100
Why?
Papillomaviridae
3
2016
18
0.100
Why?
Immunoglobulin Heavy Chains
1
2011
2
0.100
Why?
Patient Selection
3
2021
184
0.100
Why?
Paraproteinemias
1
2011
5
0.100
Why?
Class I Phosphatidylinositol 3-Kinases
1
2011
9
0.100
Why?
Proteins
1
2012
64
0.100
Why?
Therapies, Investigational
1
2011
5
0.100
Why?
Time Factors
4
2019
1347
0.100
Why?
Fluorescent Antibody Technique
3
2019
55
0.100
Why?
Myeloproliferative Disorders
1
2011
2
0.090
Why?
Vascular Diseases
1
2011
41
0.090
Why?
Risk Factors
4
2019
2221
0.090
Why?
Xanthine Dehydrogenase
1
2010
6
0.090
Why?
Apoptosis Regulatory Proteins
1
2010
11
0.090
Why?
Calcium-Calmodulin-Dependent Protein Kinases
1
2010
14
0.090
Why?
Tumor Suppressor Proteins
1
2010
34
0.080
Why?
Signal Transduction
1
2012
417
0.080
Why?
Glomerular Filtration Rate
3
2015
51
0.080
Why?
Clinical Trials, Phase III as Topic
1
2009
13
0.080
Why?
Clinical Trials, Phase II as Topic
1
2009
21
0.080
Why?
Radiotherapy
1
2009
31
0.080
Why?
Kidney Function Tests
3
2014
20
0.080
Why?
DNA Methylation
1
2010
161
0.080
Why?
Peptic Ulcer
1
2008
3
0.080
Why?
Celecoxib
1
2008
5
0.080
Why?
In Situ Hybridization
1
2008
48
0.070
Why?
Length of Stay
2
2023
290
0.070
Why?
Risk Assessment
3
2019
592
0.070
Why?
Pyrazoles
1
2008
35
0.070
Why?
Antibodies, Antineutrophil Cytoplasmic
2
2019
9
0.070
Why?
Mass Spectrometry
2
2019
36
0.070
Why?
Kidney Failure, Chronic
2
2021
146
0.070
Why?
Sensitivity and Specificity
2
2019
473
0.060
Why?
Blood Group Incompatibility
1
2005
2
0.060
Why?
Splenectomy
1
2005
5
0.060
Why?
ABO Blood-Group System
1
2005
5
0.060
Why?
Adolescent
3
2018
2172
0.060
Why?
Graft Rejection
1
2005
62
0.060
Why?
Pemetrexed
2
2015
4
0.060
Why?
Lymph Nodes
2
2016
67
0.060
Why?
Case-Control Studies
3
2012
567
0.060
Why?
Drug Administration Schedule
2
2015
154
0.060
Why?
Cyclin-Dependent Kinase Inhibitor p16
2
2018
25
0.060
Why?
Tomography, X-Ray Computed
2
2022
675
0.060
Why?
Recurrence
2
2018
288
0.060
Why?
Radiotherapy Dosage
2
2015
116
0.060
Why?
Etoposide
2
2015
24
0.060
Why?
Carboplatin
2
2015
24
0.060
Why?
Microscopy, Electron
2
2015
56
0.050
Why?
Paclitaxel
2
2015
42
0.050
Why?
Acute Disease
2
2014
190
0.050
Why?
Laryngectomy
1
2023
21
0.050
Why?
Salvage Therapy
1
2023
32
0.050
Why?
Aniline Compounds
1
2023
33
0.050
Why?
Positron Emission Tomography Computed Tomography
1
2022
34
0.050
Why?
Analysis of Variance
2
2015
259
0.050
Why?
Tumor Microenvironment
1
2022
16
0.050
Why?
Minnesota
2
2012
9
0.050
Why?
Body Mass Index
1
2024
432
0.050
Why?
Proportional Hazards Models
2
2014
321
0.050
Why?
Cetuximab
1
2021
6
0.050
Why?
Proteinuria
2
2012
57
0.050
Why?
C-Reactive Protein
1
2022
92
0.050
Why?
Phototherapy
1
2021
28
0.050
Why?
Antigens, Neoplasm
1
2021
39
0.050
Why?
Observer Variation
1
2021
96
0.040
Why?
Phenotype
1
2021
305
0.040
Why?
Genetic Heterogeneity
1
2019
9
0.040
Why?
Clinical Decision-Making
1
2019
40
0.040
Why?
Reference Values
1
2019
189
0.040
Why?
Neoplasm Invasiveness
1
2018
89
0.040
Why?
Graft Survival
1
2018
96
0.040
Why?
Radiation Pneumonitis
1
2015
3
0.030
Why?
Hemoptysis
1
2015
6
0.030
Why?
Esophagitis
1
2015
6
0.030
Why?
Cough
1
2015
9
0.030
Why?
Quality-Adjusted Life Years
1
2015
20
0.030
Why?
Markov Chains
1
2015
30
0.030
Why?
Chest Pain
1
2015
16
0.030
Why?
Radiotherapy, Adjuvant
1
2015
49
0.030
Why?
Complement C3
1
2015
6
0.030
Why?
Paraffin Embedding
1
2015
3
0.030
Why?
Tissue Fixation
1
2015
7
0.030
Why?
Radiation Injuries
1
2015
27
0.030
Why?
Dyspnea
1
2015
39
0.030
Why?
False Positive Reactions
1
2015
34
0.030
Why?
Neoplasm, Residual
1
2015
6
0.030
Why?
Diagnostic Errors
1
2015
27
0.030
Why?
Cost-Benefit Analysis
1
2015
122
0.030
Why?
Lymph Node Excision
1
2015
23
0.030
Why?
Guanine
1
2014
5
0.030
Why?
Glutamates
1
2014
9
0.030
Why?
Pyrroles
1
2014
22
0.030
Why?
Steroids
1
2014
24
0.030
Why?
Glomerular Basement Membrane
1
2014
3
0.030
Why?
Mobility Limitation
1
2015
90
0.030
Why?
Antibodies
1
2014
46
0.030
Why?
Glucocorticoids
1
2014
58
0.030
Why?
Patient Readmission
1
2015
127
0.030
Why?
Double-Blind Method
1
2014
411
0.030
Why?
Autoimmune Diseases
1
2014
48
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
2014
68
0.030
Why?
Diet
1
2015
205
0.030
Why?
Recovery of Function
1
2014
285
0.030
Why?
Laser Therapy
1
2012
9
0.030
Why?
Sequence Analysis, Protein
1
2012
4
0.020
Why?
Amino Acid Sequence
1
2012
146
0.020
Why?
Heavy Chain Disease
1
2011
2
0.020
Why?
Electrophoresis
1
2011
6
0.020
Why?
Child, Preschool
1
2014
652
0.020
Why?
Age Distribution
1
2012
84
0.020
Why?
Sex Distribution
1
2012
77
0.020
Why?
Molecular Sequence Data
1
2012
185
0.020
Why?
Digestive System Surgical Procedures
1
2011
22
0.020
Why?
Biopsy, Needle
1
2012
105
0.020
Why?
Thrombocythemia, Essential
1
2011
1
0.020
Why?
Primary Myelofibrosis
1
2011
1
0.020
Why?
Polycythemia Vera
1
2011
2
0.020
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2011
7
0.020
Why?
Echocardiography
1
2011
92
0.020
Why?
Stem Cell Transplantation
1
2011
41
0.020
Why?
Transplantation, Autologous
1
2011
159
0.020
Why?
Medical Oncology
1
2011
39
0.020
Why?
Choice Behavior
1
2011
45
0.020
Why?
Glomerulosclerosis, Focal Segmental
1
2011
35
0.020
Why?
Academic Medical Centers
1
2012
124
0.020
Why?
Activities of Daily Living
1
2015
571
0.020
Why?
Multivariate Analysis
1
2011
296
0.020
Why?
Gene Amplification
1
2010
20
0.020
Why?
Remission Induction
1
2010
70
0.020
Why?
Comorbidity
1
2012
468
0.020
Why?
Death-Associated Protein Kinases
1
2010
4
0.020
Why?
DNA Modification Methylases
1
2010
4
0.020
Why?
Monomeric GTP-Binding Proteins
1
2010
5
0.020
Why?
DNA Repair Enzymes
1
2010
7
0.020
Why?
Immunoenzyme Techniques
1
2010
28
0.020
Why?
In Situ Hybridization, Fluorescence
1
2010
34
0.020
Why?
Cadherins
1
2010
34
0.020
Why?
Antigens, CD
1
2010
50
0.020
Why?
CpG Islands
1
2010
53
0.020
Why?
Neoplasm Proteins
1
2010
50
0.020
Why?
Promoter Regions, Genetic
1
2010
93
0.020
Why?
Adaptor Proteins, Signal Transducing
1
2010
63
0.020
Why?
Child
1
2014
1326
0.020
Why?
Algorithms
1
2012
357
0.020
Why?
Clinical Trials as Topic
1
2010
211
0.020
Why?
Smoking
1
2010
164
0.020
Why?
Lung
1
2010
148
0.020
Why?
Severity of Illness Index
1
2012
853
0.020
Why?
Transplantation Conditioning
1
2005
19
0.020
Why?
Drug Therapy, Combination
1
2005
169
0.020
Why?
Tissue Donors
1
2005
78
0.020
Why?
Animals
1
2010
3551
0.010
Why?
Fidler's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (297)
Explore
_
Co-Authors (28)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_